BUSINESS
    Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool
    By Kohei Hori May 21, 2025
    Sanofi has seen positive changes in customer experiences and rep performances in Japan since the launch of its proprietary AI sales support system at its local unit in 2022, says Sabina Steinkellner, Japan general manager…

    LATEST

    LDP Commission Mulls Proposal for Price Revisions That Enable Wage Hikes on Par with Other Industries
    May 21, 2025
    The Liberal Democratic Party’s (LDP) Research Commission on Social Security System is drawing up a proposal that is expected to call for drug price revisions in FY2026 that would allow the relevant sector to achieve…
    LDP’s Pharmaceutical Security League Reboots under New Chair
    May 21, 2025
    The ruling Liberal Democratic Party’s (LDP) lawmakers league for pharmaceutical security has re-launched itself under a new leader, with the aim of discussing a wide range of policy issues including steps to ensure the quality…
    MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
    May 21, 2025
    The Ministry of Health, Labor and Welfare (MHLW) has started inviting development sponsors for five so-called “drug loss” products that are deemed medically highly necessary including the gastrointestinal stromal tumor (GIST) treatment avapritinib.The five products…

    COMMENTARY

    Impact of US Drug Policy: President Trump Shaking the World of Pharma
    By Kohei Hori

    The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…

    COLUMN

    The Evolution of HR: From BP to Agile
    By Philip Carrigan

    The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…

    Discussions on Next PMD Act Amendment

    Japan Cabinet Approves Bill to Amend PMD Act

    The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

    Drug Approval & Reimbursement in 2024

    Japan Approves Zepbound, Qalsody, and Lots More Drugs

    Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

    Chuikyo Debate on Off-Year Drug Price Revisions

    Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
    By Ken Yoshino

    Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…

    TRENDS

    Top 10 PHARMA JAPAN Articles of 2024

    For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…

    MHLW Panel on Generic Industry Structure

    MHLW Panel Draws Up Plans for Generic Industry Shakeup in Final Report

    A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

    MHLW Panel on Pharmaceutical Regulations

    Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS

    The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…

    Chuikyo on FY2024 Reimbursement Reform

    Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap

    Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

    MHLW Expert Panel on Comprehensive Policies

    Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
    By Yoshinori Sagehashi

    The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA